Nondrug Treatments for Idiopathic Pulmonary Fibrosis: IPF Part 3
نویسندگان
چکیده
"Nondrug Treatments for Idiopathic Pulmonary Fibrosis: IPF Part 3." American Journal of Respiratory and Critical Care Medicine, 203(4), pp. P10–P11
منابع مشابه
Current Concept for the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF)
Fibrosis in interstitial lung disease is caused by the accumulation of extracellular matrix proteins within the interstitium and alveolar space of the lung. The majority of severe cases comprise a classification known as idiopathic pulmonary fibrosis (IPF) for which the origin is unknown [1]. IPF is the most severe chronic form of pulmonary fibrosis and results in gradual exchange of normal lun...
متن کاملColitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
A 76-year-old Japanese man was diagnosed with idiopathic pulmonary fibrosis (IPF) based on high-resolution computed tomography (CT) (Picture A) three years prior. Nintedanib (300 mg/day) treatment was initiated to treat the IPF. Eighty-four days later, he visited our hospital with stomachache, chronic diarrhea and gross hematochezia. Abdominal contrast-enhanced CT showed bowel wall thickening (...
متن کاملUsual Interstitial Pneumonia (UIP) and Idiopathic Pulmonary Fibrosis (IPF) — Symptoms and Treatments
Idiopathic pulmonary fibrosis (IPF) belongs to a group of diseases whose specific cause is not well known, which keeps clinicians and researchers worried: the often rapid progression of IPF is very distressing. Also the underlying causes are mostly unknown, pathophysiologic explanations and findings are still unsatisfying. With only a 5-year survival rate of 20–40 %, only quick decisions such a...
متن کاملEmerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Currently, there are no approved pharmacological treatments for the management of patients with idiopathic pulmonary fibrosis (IPF) in the USA or Europe. Pirfenidone is an orally bio-available small molecule that exhibits antifibrotic and anti-inflammatory properties in a variety of in vitro and animal models. Pirfenidone has been evaluated in four randomised, double-blind, placebo-controlled c...
متن کاملAutoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
BACKGROUND Severe acute exacerbations (AE) of idiopathic pulmonary fibrosis (IPF) are medically untreatable and often fatal within days. Recent evidence suggests autoantibodies may be involved in IPF progression. Autoantibody-mediated lung diseases are typically refractory to glucocorticoids and nonspecific medications, but frequently respond to focused autoantibody reduction treatments. We con...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Respiratory and Critical Care Medicine
سال: 2021
ISSN: ['1073-449X', '1535-4970']
DOI: https://doi.org/10.1164/rccm.2034p10